0000000000732792

AUTHOR

K. Qu

showing 1 related works from this author

530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pami…

2020

Oncologymedicine.medical_specialtyTemozolomidebusiness.industryLow doseLocally advancedHematologyPARP1OncologyInternal medicinemedicineBiomarker (medicine)businessmedicine.drugAnnals of Oncology
researchProduct